Menotrophin Ferring (Menotrophin)

Menotrophin supplies exogenous follicle‑stimulating hormone (FSH) and luteinising hormone (LH). After injection, FSH binds to receptors on ovarian granulosa cells, promoting the growth and maturation of follicles, while LH activates theca‑cell receptors, supporting estrogen production and final follicular maturation, ultimately leading to ovulation.

The dosage of Menotrophin is individualized and determined by the treating physician based on the patient’s ovarian reserve, response to prior stimulation, and the specific assisted reproduction protocol. The prescriber will calculate the appropriate number of international units (IU) per injection and the duration of treatment.

Menotrophin is intended for use before conception to induce ovulation; it is not administered during an established pregnancy. Safety data for use while breastfeeding are limited, and the medication is generally avoided in lactating women unless the benefits outweigh potential risks as assessed by a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Menotrophin is a human menopausal gonadotropin (hMG) that provides both FSH and LH activity in a single preparation, whereas recombinant FSH products contain only FSH. The combined activity can be advantageous in certain protocols, reducing the need for separate LH supplementation, but the choice depends on individual patient characteristics and clinician preference.

Menotrophin should be stored refrigerated between 2 °C and 8 °C. It must be kept in its original packaging, protected from light, and should not be frozen or shaken. If the product reaches room temperature, it should be used promptly and not be re‑refrigerated.

Menotrophin is supplied as a sterile injectable solution for intramuscular or subcutaneous injection. The medication is reconstituted with the appropriate diluent, drawn into a syringe, and administered according to the dosing schedule prescribed by the treating physician, typically in the abdomen or thigh.

The most serious adverse events include ovarian hyperstimulation syndrome (OHSS), which can cause rapid ovarian enlargement, fluid shifts, and thromboembolic complications, and the possibility of multiple pregnancy, which carries higher obstetric risk. Prompt monitoring and dose adjustment are essential to mitigate these risks.

Menotrophin is contraindicated in women with known hypersensitivity to any component of the product, active ovarian cysts, uncontrolled thyroid disease, or severe ovarian hyperstimulation syndrome. It should also be avoided in patients with a history of thromboembolic disorders unless a specialist determines that benefits outweigh the risks.